You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
山東新華製藥股份(00719.HK)年度淨利增7.29%至3.49億元

格隆匯3月30日丨山東新華製藥股份(00719.HK)公佈,截至2021年12月31日止年度,公司營業收入為人民幣65.61億元,同比增長9.23%;歸屬於上市公司股東的淨利潤為人民幣3.49億元,同比增長7.29%;歸屬於上市公司股東的扣除非經常性損益的淨利潤為人民幣2.91億元,同比增長0.19%;基本每股收益為人民幣0.56元。

2021年集團克服原材料及運費迅猛漲價、人民幣大幅升值、市場需求低迷等各種困難,及時調整策略,積極迎難而上,保持了營業收入和利潤雙增長,主要經營指標連續8年創歷史新高。

報吿期內,出口創匯實現3.25億美元,同比增長10.50%,其中魚油系列產品銷售額人民幣近億元,激素系列銷售額同比增長50.2%。國內原料藥實現銷售額人民幣8.9億元,同比增長14.9%,其中獸藥同比增長40%。

製劑工業實現銷售額人民幣14億元,同比增長11.8%。10大製劑戰略品種實現銷量增長31.5%。11個保健品成功上市,採用自產高純度EPA原料打造的魚油軟膠囊產品,成為公司大健康板塊的前沿產品。公司被認定為山東省高端品牌培育企業。

固體制劑出口突破21億片,美多芭項目投入商業運營,多個國際合作項目加快推進。

新華健康與淄博市醫保局共創的"淄博互聯網+大健康平台"上線運營,與淄博市中心醫院共創"慢病管理中心",開設互聯網智慧藥房,"醫保服務""慢病服務""自主品牌"正加快形成新華特色"互聯網+醫療健康"服務生態。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account